Caley Castelein, M.D.

Caley is a founder and managing member of Kearny Venture Partners and KVP Capital.

Caley is a current board member of Alivecor, Boreal, Newbridge Pharmaceuticals, ViewRay, WellPartner, and Waterstone Pharmaceuticals. At Kearny, his previous investments include Aspreva (acquired by Gelenica), CoTherix (acquired by Actelion), Kai (acquired by Amgen), Roxro (acquired by a unit of Daiichi Sankyo), and QuatRx (partnered with Shionogi).

Caley received his M.D. from the University of California, San Francisco, with honors. During medical school, he ran a research program investigating the genetic causes of deafness and the application of gene therapy to treatment of hearing loss. The findings were published in leading journals including Nature Genetics. After medical school, Caley completed a general surgery internship at the University of California, San Francisco. He received an A.B. magna cum laude from Harvard College.